Lasmiditan for acute treatment of migraine in patients with cardiovascular risk factors: post-hoc analysis of pooled results from 2 randomized, double-blind, placebo-controlled, phase 3 trials

Overview of attention for article published in The Journal of Headache and Pain, August 2019

Altmetric Badge

About this Attention Score

Above-average Attention Score compared to outputs of the same age (64th percentile)

Mentioned by

policy: 1 policy source

twitter: 2 X users

Citations

dimensions_citation: 65 Dimensions

Readers on

mendeley: 94 Mendeley

Summary Policy documents X Dimensions citations

So far, Altmetric has seen 1 policy document that references this research output.

Lasmiditan for the Acute Treatment of Migraine

Cited by Canadian Agency for Drugs and Technologies in Health on 13 Mar 2020

CADTH is an independent, not-for-profit organization responsible for providing health care decision-makers with objective evidence to help make informed decisions about the optimal use of health technologies.

This page shows the most recent policy documents that mention this research output.

Click here to find out how to access more activity.